A 72-year-old man with localized prostate cancer (T2b, PSA 8 ng/mL, Gleason 7) is counseled regarding treatment options. He is fit for surgery and has a life expectancy >15 years. After shared decision-making, he opts for androgen deprivation therapy (ADT) combined with external beam radiation therapy (EBRT). What is the drug of choice for ADT in this intermediate-risk localized prostate cancer?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.

Daily MCQs, study tips, and topper strategies on Telegram.